Abstract YO38
Case summary
Thymomas constitute 10% of mediastinal tumours and are often benign epithelial neoplasms of the thymus gland. Up to a third of cases of thymomas are malignant and causes local infiltration to surrounding structures. Rarely, they metastasize to distant organs. We report a case of slow growing thymoma which progressed into cerebral metastases. A 53 year old lady presented with 5 years history of a mediastinal tumour. She initially refused any therapy at the first presentation. She returned with an enlarging anterior mediastinal mass causing chest pain and cough. Thoracic CT revealed a 10 cm right anterior mediastinal mass abutting the pericardium. Histopathological examination of the mediastinal mass biopsy indicated thymoma. She was planned for surgical resection however developed acute neurological symptoms of headache, confusion and memory loss. Cranial MRI showed multiple lesions in the temporoparietal lobe, left frontal lobe, internal capsule and basal ganglia. Stereotactic biopsy confirmed metastases from a B1 type thymoma. She deteriorated rapidly and died without any possible intervention. Intracranial metastases from thymic tumours are rare. To date, there are 45 cases reported within the literature of cerebral metastases from thymic epithelial tumours. The median survival with multiple cerebral metastases is merely 64 days, hence high suspicion of distant spread in thymic epithelial tumours and prompt surgery may potential improve the outcome in this group of patients.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract